BioNTech stock maintains Outperform rating at BMO on positive cancer trial

Investing.com - BMO Capital has reiterated an Outperform rating and $143.00 price target on BioNTech (NASDAQ:BNTX), currently valued at $27 billion, following positive interim trial results for its cancer treatment. According to InvestingPro data, analyst targets range from $113 to $174, suggesting potential upside.

The company’s antibody-drug conjugate BNT323/DB-1303 (trastuzumab pamirtecan) met its primary endpoint of progression-free survival in HER2-positive advanced breast cancer patients during an interim analysis.

The treatment, developed in partnership with DualityBio, demonstrated superiority against Roche’s Kadcyla, clearing the path for a regulatory submission in China.

Specific data regarding the observed survival improvement and other results from the trial have not yet been released to the public.

BMO Capital views this outcome as validation of BioNTech’s strategic partnership with DualityBio, potentially indicating positive prospects for the ongoing global Phase 3 DYNASTY-Breast02 trial, additional antibody-drug conjugate pipeline assets, and combination therapies in development.

In other recent news, BioNTech and its partner Duality Biologics announced that their experimental cancer drug met its primary endpoint in a Phase 3 trial, targeting HER2-positive unresectable or metastatic breast cancer. The drug, trastuzumab pamirtecan, demonstrated progression-free survival, marking a significant development in its clinical evaluation. BioNTech reported a net loss of €1.60 per diluted share for the second quarter of 2025, falling short of H.C. Wainwright’s forecast of €3.25 per share, with revenue significantly below expectations at €339.0 million. Meanwhile, TD Cowen raised its price target for BioNTech to $120, citing better-than-expected second-quarter Comirnaty sales of €153 million. Clear Street also increased its price target to $185, following BioNTech’s revenue of €261 million, which surpassed consensus estimates. Conversely, H.C. Wainwright lowered its price target to $136 due to increased operating expenses, while Wells Fargo adjusted its target to $150, factoring in BioNTech’s collaboration with Bristol Myers Squibb. These recent developments reflect varied analyst perspectives on BioNTech’s financial performance and strategic collaborations.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.